CDLX
Get informed when a big investor buys or sells
+ FollowUndervalued by 3118.5% based on the discounted cash flow analysis.
| Market cap | $38.87 Million |
|---|---|
| Enterprise Value | $215.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.95 |
| Beta | 0.69 |
| Outstanding Shares | 54,896,000 |
| P/E Ratio | -0.39 |
|---|---|
| PEG | 0.59 |
| Price to Sales | 0.22 |
| Price to Book Ratio | -0.65 |
| Enterprise Value to Revenue | 1.05 |
| Enterprise Value to EBIT | -7.5 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | -53.15 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2303▼ 25.84% |
|---|---|
| Total Calls | 813,300▼ 5.57% |
| Total Puts | 187,300▼ 55.50% |
Holdings and activity of institutional investors.
| Ownership % | 32.46%▼ 8.33% |
|---|---|
| Total Invested | $18.10M▼ 27.86% |
| Investors Holding | 66▼ 9.00% |
No data
This committee regulates the entire financial system, including banks, which are core partners for Cardlytics. Changes in bank capital requirements, consumer finance protection, or data sharing regulations could directly impact Cardlytics' business model and its ability to operate within financial ecosystems.
This committee's vast jurisdiction over interstate commerce, the FTC, and privacy laws is highly relevant. Cardlytics deals extensively with consumer data for advertising, making it susceptible to regulations on privacy, data security, and advertising practices overseen by this committee.